Global Oral Contraceptive Pills Market to be worth US$22.9 bn by 2023, Increasing Awareness Regarding Benefits of Contraceptive Pills Drives Growth Transparency Market Research (TMR) has recently published a study on the global oral contraceptive pills market and estimated the market to rise at a CAGR of 6.60% during the period from 2015 and 2023. The market is expected to increase from a value of US$13.1 bn in 2014 to US$22.9 bn by the end of the forecast period.The research report is titled “Oral Contraceptive Pills Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.� Contraceptive or birth control pill is a daily pill that contains hormones to change the way the body works and prevent pregnancy. Two main types of oral contraceptive pills are available in the market: combination pill containing two hormones (estrogen and progestin) and progestinonly pill. High incidence of unintended pregnancies and awareness programs organized by governments and NGOs drive the global demand for oral contraceptive pills. Moreover, increasing maternal age and late pregnancies coupled with family planning by most couples have triggered the growth of the market.
Based on the types of products, the global oral contraceptive pills market has been categorized into combination pills, progestin only pills and others. Combination pills are type of oral contraceptive pills that contain progestin and ethinyl estradiol that are similar to natural sex hormones estrogen and progesterone produced in a woman’s body. Combination pills are further segmented into monophasic, triphasic, and other (biphasic and quadriphasic) based on the level of hormones present among females during the first three weeks of the menstrual cycle. The monophasic combination pills sub-segment accounted for nearly majority of the market share of the combination pills segment in 2014 due to higher effectiveness and growing preference for monophasic pills. Monophasic pills are available in three different doses of estrogen: low dose (20 mcg), regular dose (30 mcg to 35 mcg), and high dose (50 mcg). Low estrogen monophasic pills cause less bloating or breast tenderness. Hence, most women consider monophasic pill as a first line of choice for contraception. Based on category, the global oral contraceptive pills market has been segmented into branded and generic oral contraceptive pills. Globally, the market is dominated by generic contraceptive pills due to availability of cost effective (low cost) drugs with similar bioavailability and bioequivalence as the branded drugs, rising preference for generic drugs among patients, and growing awareness about unintended pregnancies. This situation is more intense in the
developing nations in Asia Pacific. The market in the region is expected to expand at the highest CAGR during the forecast period. Browse Full Research Report on Oral Contraceptive Pills Market: http://www.transparencymarketresearch.com/oral-contraceptive-pills-market.html Geographically, the global contraceptive pills market has been differentiated into the following regions: North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America dominated the global contraceptive pills market in 2014 due to the high incidence rate of unintended pregnancies, availability of favorable reimbursement policies after implementation of the Affordable Care Act and increased use of emergency contraceptive pills and oral contraceptive pills. On the other hand, Asia Pacific is estimated as the most opportunistic market during the forecast period due to strong economic growth in countries such as India, China, Singapore, Philippines, Australia, and others. This in turn, has led to increased awareness about the use of contraception for pregnancy prevention, rising disposable income and demand for healthy life, which is increasing the adoption rate of contraceptive pills in Asia Pacific. The global contraceptive pills market is characterized by the presence of major companies such as Actavis, Inc., Bayer AG, Church & Dwight, Co., Inc., Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mankind Pharma, and Piramal Enterprises Ltd. These market players are engaged in growth strategies such as acquisitions, marketing of products (providing free samples or contraceptives in reduced prices) and introducing various awareness programs to increase the market share and sustain in the highly competitive contraceptive pills market.
Browse Full Press Release on Oral Contraceptive Pills Market: Press Release About Us Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact Us Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com